Disclaimer: This site aggregates publicly available data from official government sources (FDA, ClinicalTrials.gov, PubMed, SEC EDGAR, NMPA) for general reference only. It does NOT constitute medical advice, diagnosis, treatment recommendations, or investment advice.

Clinical Trial

REsponse to Combined SONS and ONS in Chronic Cluster headachE

NCT: NCT05868044 · ACTIVE_NOT_RECRUITING

NCT IDNCT05868044
StatusACTIVE_NOT_RECRUITING
Start Date2023-05-02
Completion2026-12-30

Brief Summary

The purpose of this study is to demonstrate the safe use of the PRIMUS System in subjects with chronic cluster headache. This is a single-centre, open label, prospective, first in human study to collect initial clinical data on the PRIMUS system for the treatment of chronic cluster headache.

Frequently Asked Questions

What is REsponse to Combined SONS and ONS in Chronic Cluster headachE?

REsponse to Combined SONS and ONS in Chronic Cluster headachE is a clinical trial registered under NCT05868044. Current status: ACTIVE_NOT_RECRUITING.

What is the status of NCT05868044?

The current status of NCT05868044 (REsponse to Combined SONS and ONS in Chronic Cluster headachE) is: ACTIVE_NOT_RECRUITING.

When did REsponse to Combined SONS and ONS in Chronic Cluster headachE start?

REsponse to Combined SONS and ONS in Chronic Cluster headachE started on 2023-05-02.

Official Source

View on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov API. For the most current status, refer to the official record.

↑